Hf 2022: Pooled Analysis Of Define-Hf And Preserved-Hf | Dr Mikhail Kosiborod

HF 2022: Pooled Analysis of DEFINE-HF and PRESERVED-HF | Dr Mikhail Kosiborod

HF 2022: 2022 Heart Failure Highlights with Dr Mikhail Kosiborod

Researcher comment: The DEFINE-HF trial | Mikhail Kosiborod

Medicine Matters diabetes

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status | Mikhail Kosiborod

Medicine Matters diabetes

Mikhail Kosiborod, MD: DAPA-HF and DEFINE-HF Findings

HF 2022: Heart Failure Highlights of 2022 with Prof John Cleland

HF 2022: DELIVER Extends Benefits of Dapagliflozin to the Full Spectrum of Pts with HF

Masterclass: Evidence on the Use of SGLT2is in HF Across the EF Spectrum

DAPA-HF clinical trial I Dapagliflozin I HFrEF

Learning Cardiology

HF 2022: CCM Therapy in Patients With HFpEF | Dr Cecilia Linde

HF 2022: CLOROTIC: Combined Loop With Thiazide Diuretics in Pts With Decompensated HF | Dr Trullas

HF 2022: Heart Failure Highlights with Prof Giuseppe Rosano

HF 2022: Chronic & Acute HF Guidelines for Patients: Improving Patient Adherence | Prof Tiny Jaarsma

Pooled Analysis DAPA HF and DELIVER - Pardeep S. Jhund, MBChB, MSc, PhD

Pardeep Jhund, ESC 2022: Dapagliflozin for heart failure, pooled analysis of DAPA-HF and DELIVER

Touch Medical Media Services

LINC 2022: ANEUFIX Novel Treatment for Type II Endoleak With Dr Hoksbergen

HFA 23: DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction

AHA 22: Late-Breaker Discussion: The STRONG-HF Trial

AHA 22: EMPEROR-POOLED: Clinical Outcomes & Efficacy of Empagliflozin in Black vs White Pts With HF